Cardiomiopatía cirrótica – ¿Realidad clínica o simple curiosidad académica? Revisión. : Parte 2: ECG, pruebas funcionales, estudios con imágenes, biomarcadores, screening para enfermedad coronaria y diagnósticos diferenciales

Hugo Ramos; Mario Altieri

doi:10.31053/1853.0605.v81.n2.44419

Autores/as

Hugo R. Ramos, M.D., Ph.D. Facultad de Ciencias Médicas, Universidad Nacional de Córdoba. División Cardiología, Instituto Modelo de Cardiologia
Mario H. Altieri, M.D. Service de Médecine, Centre Hospitalier Marguerite de Lorraine, Mortagne au Perche, France

DOI:

https://doi.org/10.31053/1853.0605.v81.n2.44419

Palabras clave:

cirrosis hepática, cardiomiopatía, insuficiencia cardíaca, biomarcadores, imágenes

Resumen

El diagnóstico de Cardiomiopatía Cirrótica está basado en la presencia de cirrosis hepática avanzada con alteraciones de la función cardíaca sin cardiopatía pre-existente, pero en gran parte de su evolución natural ésta es subclínica. Por ello son imprescindibles los estudios complementarios no invasivos para confirmar el diagnóstico y su rol pronóstico en pacientes con o sin trasplante hepático. En esta segunda parte revisamos los métodos de diagnóstico desde el ECG hasta las imágenes de resonancia magnética cardíaca.

Descargas

Los datos de descarga aún no están disponibles.

Biografía del autor/a

Hugo R. Ramos, M.D., Ph.D., Facultad de Ciencias Médicas, Universidad Nacional de Córdoba. División Cardiología, Instituto Modelo de Cardiologia

Egresado de la Universidad Nacional de Córdoba. Especialista en Clínica Médica, Especialista en Cardiología (CMPC y UNC), Especialista en Medicina de Emergencias (CMPC). Doctor en Medicina y Cirugía FCM, UNC. Ex Jefe del Depto de Clínica Médica del Hospital Municipal de Urgencias de Córdoba, Cardiólogo en Instituto Modelo de Cardiología de Córdoba. Prof. Asociado en la Cátedra de Clínica Médica I, UHMI 2 del Hospital San Roque, FCM, UNC. Campo de investigación: biomarcadores cardíacos, insuficiencia cardíaca, amiloidosis cardíaca, cardiopatía isquémica. ORCID ID: https://orcid.org/0000-0001-6772-903X
Mario H. Altieri, M.D., Service de Médecine, Centre Hospitalier Marguerite de Lorraine, Mortagne au Perche, France

Egresado de la Universidad Nacional de Córdoba. Especialista en Medicina Interna y Terapia Intensiva (CMPC), Especialista en Terapia Intensiva (Francia). Ex Prof. de Medicina Intensiva de la Universidad Católica de Córdoba. Ex Director del programa Medicob de trasplante de Hígado, Caen, Francia. Miembro fundador del Cirrhotic Cardiomyopathy Consortium. Ex Miembro del Comité Ejecutivo de la International Liver Transplant Society (ILTS) para problemas cardiovasculares y cirrosis. ORCID ID: https://orcid.org/0000-0003-4164-1771.

Referencias

1. Marchetta S, Altieri M, Weil-Verhoeven D, Mouhat B, Piérard L, Thévenot T. La cardiomyopathie cirrhotique: de nouvelles approches diagnostiques. Hépato-Gastro et Oncologie Digestive 2021;28:584-592.

2. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998 Jan;27(1):28-34. doi: 10.1002/hep.510270106

3. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002 Apr;36(4):513-20. doi: 10.1016/s0168-8278(02)00010-7.

4. Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, Lenzi B, Caraceni P, Domenicali M, Cavazza M, Bernardi M. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int. 2012 Nov;32(10):1510-5. doi: 10.1111/j.1478-3231.2012.02847.x.

5. Ahn JC, Attia ZI, Rattan P, Mullan AF, Buryska S, Allen AM, Kamath PS, Friedman PA, Shah VH, Noseworthy PA, Simonetto DA. Development of the AI-Cirrhosis-ECG Score: An Electrocardiogram-Based Deep Learning Model in Cirrhosis. Am J Gastroenterol. 2022 Mar 1;117(3):424-432. doi: 10.14309/ajg.0000000000001617.

6. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.

7. Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hoppmann R, Breitkreutz R, Seibel A, Neri L, Storti E, Petrovic T; International Liaison Committee on Lung Ultrasound (ILC-LUS) for International Consensus Conference on Lung Ultrasound (ICC-LUS). International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012 Apr;38(4):577-91. doi: 10.1007/s00134-012-2513-4.

8. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014. Erratum in: Eur Heart J Cardiovasc Imaging. 2016 Apr;17(4):412. Erratum in: Eur Heart J Cardiovasc Imaging. 2016 Sep;17 (9):969.

9. Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11. Erratum in: Hepatology. 2020 Sep;72(3):1161.

10. Mirea O, Pagourelias ED, Duchenne J, Bogaert J, Thomas JD, Badano LP, Voigt JU; EACVI-ASE-Industry Standardization Task Force. Variability and Reproducibility of Segmental Longitudinal Strain Measurement: A Report From the EACVI-ASE Strain Standardization Task Force. JACC Cardiovasc Imaging. 2018 Jan;11(1):15-24. doi: 10.1016/j.jcmg.2017.01.027.

11. Kwon HM, Moon YJ, Jung KW, Park YS, Kim KS, Jun IG, Song JG, Hwang GS. Appraisal of Cardiac Ejection Fraction With Liver Disease Severity: Implication in Post-Liver Transplantation Mortality. Hepatology. 2020 Apr;71(4):1364-1380. doi: 10.1002/hep.30913.

12. Rimbaș RC, Rimbas M, Chitroceanu AM, Luchian LM, Pop C, Vinereanu D. Cirrhotic Cardiomyopathy in the Era of Liver Transplantation: Time for Precise Stepwise Evaluation. J Gastrointestin Liver Dis. 2020 Dec 13;29(4):665-675. doi: 10.15403/jgld-3137.

13. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016 Apr;29(4):277-314. doi: 10.1016/j.echo.2016.01.011.

14. Lang RM, Addetia K, Narang A, Mor-Avi V. 3-Dimensional Echocardiography: Latest Developments and Future Directions. JACC Cardiovasc Imaging. 2018 Dec;11(12):1854-1878. doi: 10.1016/j.jcmg.2018.06.024.

15. Ozersari S, Ünal B, Kemal Çabuk A, Eren Hazir K, Çağri Şimşek E, Ekmekci C, Küçükukur M, Betül Paköz Z, Günay S, Sari C. The prognostic value of P-wave dispersion and left atrial functions assessed with three-dimensional echocardiography in patients with cirrhosis. Eur J Gastroenterol Hepatol. 2021 Nov 1;33(11):1441-1450. doi: 10.1097/MEG.0000000000002129.

16. Wiese S, Liang M, Mo S, Bendtsen F, Hove JD, Møller S. Left atrial volume changes assessed by real time 3-dimensional echocardiography in relation to liver function and prognosis in patients with cirrhosis. Int J Cardiovasc Imaging. 2020 Nov;36(11):2121-2127. doi: 10.1007/s10554-020-01920-7.

17. Karagodin I, Genovese D, Kruse E, Patel AR, Rashedi N, Lang RM, Mor-Avi V. Contrast-enhanced echocardiographic measurement of longitudinal strain: accuracy and its relationship with image quality. Int J Cardiovasc Imaging. 2020 Mar;36(3):431-439. doi: 10.1007/s10554-019-01732-4.

18. Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, Flamm SL, Blei AT, Bonow RO, Abecassis M, Gheorghiade M. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. Am J Transplant. 2008 Jul;8(7):1523-8. doi: 10.1111/j.1600-6143.2008.02276.x.

19. Barbosa M, Guardado J, Marinho C, Rosa B, Quelhas I, Lourenço A, Cotter J. Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis? World J Hepatol. 2016 Jan 28;8(3):200-6. doi: 10.4254/wjh.v8.i3.200.

20. Doytchinova AT, Feigenbaum TD, Pondicherry-Harish RC, Sepanski P, Green-Hess D, Feigenbaum H, Sawada SG. Diagnostic Performance of Dobutamine Stress Echocardiography in End-Stage Liver Disease. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 1):2115-2122. doi: 10.1016/j.jcmg.2018.10.031.

21. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, Douglas DD. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010 Dec;16(12):1373-8. doi: 10.1002/lt.22167.

22. Dharancy S, Lemyze M, Boleslawski E, Neviere R, Declerck N, Canva V, Wallaert B, Mathurin P, Pruvot FR. Impact of impaired aerobic capacity on liver transplant candidates. Transplantation. 2008 Oct 27;86(8):1077-83. doi: 10.1097/TP.0b013e318187758b.

23. Ow MM, Erasmus P, Minto G, Struthers R, Joseph M, Smith A, Warshow UM, Cramp ME, Cross TJ. Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation. Liver Transpl. 2014 Sep;20(9):1081-8. doi: 10.1002/lt.23907.

24. Ney M, Haykowsky MJ, Vandermeer B, Shah A, Ow M, Tandon P. Systematic review: pre- and post-operative prognostic value of cardiopulmonary exercise testing in liver transplant candidates. Aliment Pharmacol Ther. 2016 Oct;44(8):796-806. doi: 10.1111/apt.13771.

25. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009 Dec 30;11(1):56. doi: 10.1186/1532-429X-11-56.

26. Taylor AJ, Salerno M, Dharmakumar R, Jerosch-Herold M. T1 Mapping: Basic Techniques and Clinical Applications. JACC Cardiovasc Imaging. 2016 Jan;9(1):67-81. doi: 10.1016/j.jcmg.2015.11.005.

27. Aherne E, Chow K, Carr J. Cardiac T1 mapping: Techniques and applications. J Magn Reson Imaging. 2020 May;51(5):1336-1356. doi: 10.1002/jmri.26866.

28. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, Salerno M, Teague SD, Valsangiacomo-Buechel E, van der Geest RJ, Bluemke DA. Reference ranges ("normal values") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87. doi: 10.1186/s12968-020-00683-3. Erratum in: J Cardiovasc Magn Reson. 2021 Oct 18;23(1):114.

29. Sampaio F, Lamata P, Bettencourt N, Alt SC, Ferreira N, Kowallick JT, Pimenta J, Kutty S, Fraga J, Steinmetz M, Bettencourt P, Gama V, Schuster A. Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. J Cardiovasc Magn Reson. 2015 Jul 18;17(1):61. doi: 10.1186/s12968-015-0157-6.

30. Wiese S, Hove J, Mo S, Mookerjee RP, Petersen CL, Vester-Andersen MK, Mygind ND, Goetze JP, Kjaer A, Bendtsen F, Møller S. Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. Liver Int. 2018 Sep;38(9):1614-1623. doi: 10.1111/liv.13870.

31. Wiese S, Hove JD, Mo S, Mygind ND, Tønnesen J, Petersen CL, Clemmesen JO, Goetze JP, Bendtsen F, Møller S. Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. Am J Physiol Gastrointest Liver Physiol. 2019 Sep 1;317(3):G253-G263. doi: 10.1152/ajpgi.00402.2018.

32. Kim HM, Kim HK, Lee JH, Lee YB, Park EA, Park JB, Lee SP, Kim YJ, Kim YJ, Yoon JH, Sohn DW. Myocardial structural and functional changes in patients with liver cirrhosis awaiting liver transplantation: a comprehensive cardiovascular magnetic resonance and echocardiographic study. J Cardiovasc Magn Reson. 2020 Apr 23;22(1):25. doi: 10.1186/s12968-020-00622-2.

33. O'Glasser AY, Scott DL, Corless CL, Zaman A, Sasaki A, Gopal DV, Rayhill SC, Orloff SL, Ham JM, Rabkin JM, Flora K, Davies CH, Broberg CS, Schwartz JM. Hepatic and cardiac iron overload among patients with end-stage liver disease referred for liver transplantation. Clin Transplant. 2010 Sep-Oct;24(5):643-51. doi: 10.1111/j.1399-0012.2009.01136.x.

34. Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes. Transplant Direct. 2018 Jun 8;4(7):e363. doi: 10.1097/TXD.0000000000000803.

35. Park J, Lee SH, Han S, Jee HS, Lee SK, Choi GS, Kim GS. Preoperative cardiac troponin level is associated with all-cause mortality of liver transplantation recipients. PLoS One. 2017 May 23;12(5):e0177838. doi: 10.1371/journal.pone.0177838.

36. Wiese S, Mortensen C, Gøtze JP, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. Liver Int. 2014 Jul;34(6):e19-30. doi: 10.1111/liv.12428.

37. Jankowski K, Trzebicki J, Bielecki M, Łągiewska B, Kurnicka K, Koczaj-Bremer M, Pacholczyk M, Pruszczyk P. Prognostic value of perioperative assessment of plasma cardiac troponin I in patients undergoing liver transplantation. Acta Biochim Pol. 2017;64(2):331-337. doi: 10.18388/abp.2016_1436.

38. Li M, Guo Z, Zhang D, Xu X, Romeiro FG, Mancuso A, Zhang J, Feng R, Zhou X, Hong C, Qi X. Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis. Gastroenterol Res Pract. 2020 Sep 24;2020:4019289. doi: 10.1155/2020/4019289.

39. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, Moreau R, Langlet P, Elman A, Bernuau J, Valla D, Erlinger S, Lebrec D. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology. 1999 Mar;29(3):640-3. doi: 10.1002/hep.510290332.

40. Ramos H, de Bold AJ. Gene expression, processing, and secretion of natriuretic peptides: physiologic and diagnostic implications. Heart Fail Clin. 2006 Jul;2(3):255-68. doi: 10.1016/j.hfc.2006.08.005.

41. Mihailovici AR, Donoiu I, Gheonea DI, Mirea O, Târtea GC, Buşe M, Calborean V, Obleagă C, Pădureanu V, Istrătoaie O. NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis - Correlations with Disease Severity. Med Princ Pract. 2019 Apr 16;28(5):432–41. doi: 10.1159/000499930.

42. Liu H, Hwang SY, Lee SS. Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy. Pharmaceuticals (Basel). 2023 Jul 7;16(7):978. doi: 10.3390/ph16070978.

43. Zivlas C, Triposkiadis F, Psarras S, Giamouzis G, Skoularigis I, Chryssanthopoulos S, Kapelouzou A, Ramcharitar S, Barnes E, Papasteriadis E, Cokkinos D. Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3. Ther Adv Cardiovasc Dis. 2017 Nov;11(11):283-295. doi: 10.1177/1753944717727498.

44. Bhatti S, Lizaola-Mayo B, Al-Shoha M, Garcia-Saenz-de-Sicilia M, Habash F, Ayoub K, Karr M, Ahmed Z, Borja-Cacho D, Duarte-Rojo A. Use of Computed Tomography Coronary Calcium Score for Coronary Artery Disease Risk Stratification During Liver Transplant Evaluation. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):319-328. doi: 10.1016/j.jceh.2021.08.015.